Get started
Author

Javier Casas‐Limón

Observed names: Casas Limón, Javier, Casas-Limón J, Casas-Limón, Javier, J. Casas Limón, J. Casas-Limón, Javier Casas Limón, Javier Casas-Limón
ORCID: 0000-0002-7353-4084
Observed ORCID: 0000-0002-7353-4084
OpenAlex ID: A5031161724
Machine‐learning‐based approach for predicting response to anti‐calcitonin gene‐related peptide ( CGRP) receptor or ligand antibody treatment in patients with migraine: A multicenter Spanish study
2022 · Alicia Gonzalez‐Martinez, Josué Pagán, et al. · European Journal of Neurology · 51
PDF
Epicrania Fugax: 19 Cases of an Emerging Headache
2013 · María Luz Cuadrado, Carlos M. Ordás, et al. · Headache The Journal of Head and Face Pain · 36
Unravelling Migraine Stigma: A Comprehensive Review of Its Impact and Strategies for Change
2024 · Casas-Limón J, Quintas S, et al. · Journal of Clinical Medicine · 35
PDF
Infratrochlear neuralgia: A prospective series of seven patients treated with infratrochlear nerve blocks
2017 · Rocío-Nur Villar-Quiles, Héctor García-Moreno, et al. · Cephalalgia · 17
PDF
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study
2023 · Alicia Gonzalez-Martinez, Ancor Sanz-García, et al. · Pain Medicine · 12
PDF
Increase in Body Temperature During Migraine Attacks
2013 · Carlos M. Ordás, María L. Cuadrado, et al. · Pain Medicine · 11
Pain Paroxysms With Coronal Radiation: Case Series and Proposal of a New Variant of Epicrania Fugax
2016 · Javier Casas‐Limón, María L. Cuadrado, et al. · Headache The Journal of Head and Face Pain · 9
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2025 · Albert Muñoz-Vendrell, Sergio Campoy-Díaz, et al. · The Journal of Headache and Pain · 8
SAFE-CGRP study: multicenter retrospective evaluation of the safety of CGRP pathway–targeting monoclonal antibodies in migraine with relevant comorbidities or conditions excluded from trials
2025 · Cristina Sanabria-Gago, Iris Fernández Lázaro, et al. · Frontiers in Neurology · 8
PDF
Concomitant anti-CGRP and immunomodulatory treatments in patients with migraine: towards integrated management strategies
2025 · María Clara García-Castillo, Álvaro Sierra-Mencía, et al. · Journal of Neurology · 8
PDF
Greater Occipital Nerve Blockade: A Safe and Effective Option for the Acute Treatment of Hemiplegic Aura
2015 · Javier Casas‐Limón, Ángel Aledo‐Serrano, et al. · Headache The Journal of Head and Face Pain · 7
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
2024 · María Pilar Navarro-Pérez, Vicente González-Quintanilla, et al. · Frontiers in Neurology · 6
PDF
Real-world experience of OnabotulinumtoxinA treatment in female patients with chronic migraine: a qualitative study using in-depth interviews
2023 · Domingo Palacios-Ceña, Carlos Ordás-Bandera, et al. · Annals of Medicine · 6
PDF
Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO ‐ CGRP study
2026 · María Clara García‐Castillo, Álvaro Sierra‐Mencía, et al. · Headache The Journal of Head and Face Pain · 4
Evaluation of the concomitant use of prophylactic treatments in patients with migraine under anti‐calcitonin gene‐related peptide therapies: The PREVENAC study
2024 · Ana Beatriz Gago‐Veiga, Noelia Lopez‐Alcaide, et al. · European Journal of Neurology · 4
PDF
Consenso sobre anticuerpos monoclonales en migraña del Grupo de Estudio de Cefaleas de la Asociación Madrileña de Neurología
2023 · Alba Cárcamo Fonfría, Álex Jaimes Sánchez, et al. · Kranion · 2
PDF
Atogepant for migraine in real-world clinical practice: Insights from a large multicentre study in a treatment-resistant population (GEMA project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · Cephalalgia · 1
Long-term atogepant for treatment-resistant migraine in real-world clinical practice: 12-month results (gema project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · The Journal of Headache and Pain
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project)
2026 · Ana Beatriz Gago-Veiga, Ana Belen Lopez-Rodriguez, et al. · Cephalalgia
ESTELA‐Study: Long‐Term Effectiveness and Safety of Anti‐Calcitonin Gene‐Related Peptide Monoclonal Antibodies in Real‐World Clinical Practice
2026 · Alba Somovilla, Iris Fernández‐Lázaro, et al. · Brain and Behavior
Atogepant after anti-CGRP monoclonal antibodies failure in migraine: a multicenter real-world study of effectiveness, safety, persistence and predictors of response
2026 · Muñoz-Vendrell, Albert, Campoy-Díaz, Sergio, et al. · Figshare
22637 - Atogepant, Una Nueva Alternativa Terapéutica En El Paciente Con Migraña Resistente: Estudio Multicéntrico De Eficacia Y Seguridad (proyecto Gema)
2025 · A. Gago Veiga, I. Fernández Lázaro, et al. · Neurology Perspectives
22835 - Atogepant Tras Fracaso a Anticuerpos Monoclonales Anticgrp En Migraña: Estudio Multicéntrico En Vida Real
2025 · A. Muñoz Vendrell, S. Campoy, et al. · Neurology Perspectives
22678 - Rimegepant Como Tratamiento Preventivo En Vida Real: Resultados De Eficacia Y Seguridad En Pacientes Con Y Sin Tratamiento Previo Con Anti-cgrp (proyecto Gema)
2025 · A. Gago Veiga, I. Fernández Lázaro, et al. · Neurology Perspectives
21657. Lasmiditán Para El Tratamiento Agudo De La Migraña: Eficacia Y Tolerabilidad
2024 · J. Contreras Peña, D. González Antón, et al. · Neurology Perspectives
Works count: 32
Citation count: 225
H-index: 8
I10-index: 6
Year
Topic
Type